D57.454
Sickle-cell thalassemia beta plus with dactylitis
Clinical Classification Guidelines
Medical Intelligence & Overview
Sickle-cell thalassemia beta plus with dactylitis is a specific type of blood disorder that affects the production of hemoglobin, the protein responsible for carrying oxygen throughout the body. This condition combines aspects of sickle cell disease and thalassemia, leading to abnormal shaped red blood cells and anemia. The term 'beta plus' indicates a form of thalassemia with some residual hemoglobin production. A notable feature of this disorder is dactylitis, characterized by swelling and pain in the fingers and toes, often an early sign of the disease. Understanding this condition can help patients and caregivers recognize symptoms and manage the disease effectively.
Causes & Symptoms
Clinical Causes: Genetic mutations inherited from parents that affect hemoglobin production Inheritance of defective genes for sickle cell hemoglobin (HbS) and beta thalassemia Combination of two genetic abnormalities leading to a mixed hemoglobinopathy
Key Symptoms: Dactylitis – swelling and pain in the fingers and toes Chronic anemia causing fatigue and weakness Jaundice or yellowing of the skin and eyes Frequent infections Delayed growth and development in children Bone pain or deformities due to marrow expansion Episodes of painful crises often triggered by dehydration, illness, or stress
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of blood tests and clinical evaluation. Key steps include: - **Blood Tests:** Complete blood count (CBC) to assess anemia, hemoglobin electrophoresis to identify abnormal hemoglobin types, and genetic testing to confirm mutations. - **Physical Examination:** Assessment for signs of anemia, jaundice, and swelling in fingers and toes. - **Imaging:** X-rays may be used to detect bone abnormalities associated with sickle-cell disease. - **Evaluation of Symptoms:** Documenting episodes of dactylitis and other manifestations helps in diagnosis.
Treatment Protocols: While there is no universal cure for sickle-cell thalassemia beta plus with dactylitis, various management strategies aim to reduce symptoms and prevent complications: - **Pain Management:** Use of pain relievers during crises; supportive care. - **Blood Transfusions:** To treat severe anemia and prevent stroke or other organ damage. - **Medications:** Hydroxyurea may be prescribed to reduce the frequency of crises and improve blood flow. - **Infection Prevention:** Immunizations and antibiotics to prevent infections. - **Monitoring and Regular Check-Ups:** Ongoing medical supervision to detect and address complications early. - **Gene Therapy (Research Stage):** Emerging treatments aim to modify genetic material to correct hemoglobin production, though not widely available yet. - **Supportive Care:** Nutritional support and psychological counseling to improve quality of life.
Clinical Advice & FAQs
Billing Guidance
Is D57.454 a billable ICD-10 code?
Yes, D57.454 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.454?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta plus with dactylitis and any associated comorbidities for accurate reporting.
Cite this Clinical Reference